Senseonics became the first company to bring a year-long continuous glucose monitor (CGM) to market with the launch of its Eversense 365 implantable system in 2024. The sensor system is different than existing transcutaneous sensors from Abbott and Dexcom, which use a small needle to measure glucose in the interstitial fluid under a patient’s skin…
The post The first year-long CGM implant developer isn’t done yet appeared first on Medical Design and Outsourcing.